Bristol-Meyers Squibb has been working with ZymoGenetics to also develop a potential hepatitis C treatment.

FORBES: After Hours: Bristol-Meyers Squibb's Acquisition

Prior to Disney, Scott was chief technology officer at GM and vice president of operations at Bristol-Meyers Squibb.

FORBES: Magazine Article

In February, Bristol-Meyers Squibb (NYSE:BMY) acquired Inhibitex (NASDAQ:INH).

FORBES: IPOs, FDA Approvals, and M&A Revive the Biotechnology Industry